Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 182-193

  Yu, Zhiqi ^a,c   Zhang, Chang ^a   Wang, Hao ^a   Xing, Junjie ^a   Gong, Haifeng ^a   Yu, Enda ^a   Zhang, Wei ^a   Zhang, Xiaoqing ^a   Cao, Guangwen ^b   Fu, Chuangang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c 306 HOSPITAL OF PLA   (China)

Author keywords

Caspase 3; Multidrug resistance associated protein 3; Neoadjuvant chemoradiotherapy; Poly ADP ribose polymerase; Reactive oxygen species; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CASPASE 3; FLUOROURACIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC ANTIMETABOLITE; CASP3 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION RESPONSE; RADIOSENSITIVITY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; TUMOR GROWTH; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; CHEMORADIOTHERAPY; DRUG EFFECT; DRUG SCREENING; HT 29 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT CHEMORADIOTHERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; POLY ADP-RIBOSE POLYMERASE; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RECTUM TUMOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ANIMALIA;

CASPASE-3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; NEOADJUVANT CHEMORADIOTHERAPY; POLY ADP-RIBOSE POLYMERASE; REACTIVE OXYGEN SPECIES; RECTAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HT29 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RECTAL NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84908663521     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.025     Document Type: Article

References (43)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin 2012, 62:10-29.
2. De Caluwé L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst. Rev 2013, (2). CD006041.
3. Ryan R., Gibbons D., Hyland J.M., et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005, 47:141-146.
4. Rees D.C., Johnson E., Lewinson O. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol 2009, 10:218-227.
5. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775:237-262.
6. Sasaki T., Hirota T., Ryokai Y., et al. Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function. Drug Metab. Pharmacokinet 2011, 26:374-386.
7. Bottke D., Koychev D., Busse A., et al. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat. Res 2008, 170:41-48.
8. Bartkowiak D., Stempfhuber M., Wiegel T., et al. Radiation- and chemoinduced multidrug resistance in colon carcinoma cells. Strahlenther. Onkol 2009, 185:815-820.
9. Grant C.E., Gao M., DeGorter M.K., et al. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab. Dispos 2008, 36:2571-2581.
10. Engstrom P.F., Arnoletti J.P., Benson A.B., et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J. Natl. Compr. Canc. Netw 2009, 7:838-881.
11. Yu Z.Q., Zhang C., Gao X.H., et al. Impacts of preoperative radiochemotherapy on operation and postoperative complications in patients with mid-low rectal carcinomas. Zhonghua Wei Chang Wai Ke Za Zhi 2012, 15:332-335.
12. Bouzourene H., Bosman F.T., Seelentag W., et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002, 94:1121-1130.
13. Amundson S.A., Do K.T., Vinikoor L.C., et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008, 68:415-424.
14. Dunne A.L., Price M.E., Mothersill C., et al. Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. Br. J. Cancer 2003, 89:2277-2283.
15. Fertil B., Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys 1985, 11:1699-1707.
16. Yu Z.Q., Zhang C., Wang H., et al. Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma. Dis. Colon Rectum 2013, 56:600-608.
17. Korystov Y.N., Shaposhnikova V.V., Korystova A.F., et al. Detection of reactive oxygen species induced by radiation in cells using the dichlorofluorescein assay. Radiat. Res 2007, 168:226-232.
18. Monson J.R., Weiser M.R., Buie W.D., et al. Practice parameters for the management of rectal cancer (revised). Dis. Colon Rectum 2013, 56:535-550.
19. Gao X.H., Liu Q.Z., Chang W., et al. Expression of ZNF148 in different developing stages of colorectal cancer and its prognostic value: a large Chinese study based on tissue microarray. Cancer 2013, 119:2212-2222.
20. Chang W., Gao X., Han Y., et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut 2013, 10.1136/gutjnl-2013-305475.
21. König J., Hartel M., Nies A.T., et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer 2005, 115:359-367.
22. Steinbach D., Wittig S., Cario G., et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003, 102:4493-4498.
23. Hinoshita E., Uchiumi T., Taguchi K., et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res 2000, 6:2401-2407.
24. Campa D., Vodicka P., Pardini B., et al. Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk?. Eur. J. Cancer 2008, 44:854-857.
25. Scheffer G.L., Kool M., de Haas M., et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest 2002, 82:193-201.
26. Zimmermann C., Gutmann H., Hruz P., et al. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos 2005, 33:219-224.
27. Theile D., Grebhardt S., Haefeli W.E., Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem. Pharmacol 2009, 78:1366-1373.
28. Jiang H., Chen K., He J., et al. Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J. Gastrointest. Surg 2009, 13:1831-1838.
29. Rödel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol 2005, 23:8688-8696.
30. Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11:835-844.
31. Katz D., Ito E., Liu F.F. On the path to seeking novel radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys 2009, 73:988-996.
32. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4:592-603.
33. Barcellos-Hoff M.H., Park C., Wright E.G. Radiation and the microenvironment - tumorigenesis and therapy. Nat. Rev. Cancer 2005, 5:867-875.
34. Qu Y., Zhao S., Hong J., Tang S. Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase. J. Cancer Res. Clin. Oncol 2010, 136:953-959.
35. Leitner H.M., Kachadourian R., Day B.J. Harnessing drug resistance: using ABC transporter proteins to target cancer cells. Biochem. Pharmacol 2007, 74:1677-1685.
36. Rappa G., Lorico A., Flavell R.A., et al. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997, 57:5232-5237.
37. Ballatori N., Hammond C.L., Cunningham J.B., et al. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol 2005, 204:238-255.
38. Lo Y.L., Wang W. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem. Biol. Interact 2013, 205:188-197.
39. Tatebe S., Sinicrope F.A., Kuo M.T. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem. Biophys. Res. Commun 2002, 290:1427-1433.
40. Hu W., Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003, 4:721-729.
41. Johnstone R.W., Cretney E., Smyth M.J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999, 93:1075-1085.
42. Decker P., Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol 2002, 3:275-283.
43. + depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death?. Acta Physiol. (Oxf.) 2011, 203:225-234.